Skip to main content
Swedish Orphan Biovitrum logo

Swedish Orphan Biovitrum — Investor Relations & Filings

Ticker · SOBI ISIN · SE0000872095 LEI · 549300124Y3MQI87PT35 ST Manufacturing
Open in API
Filings indexed 892 across all filing types
Latest filing 2024-10-24 Interim / Quarterly Rep…
Country SE Sweden
Listing ST SOBI

About Swedish Orphan Biovitrum

https://www.sobi.com/en

Swedish Orphan Biovitrum (Sobi) is a specialized biopharmaceutical company dedicated to developing and delivering innovative treatments for rare and debilitating diseases. The company's primary focus is on the therapeutic areas of haematology and immunology, with a significant legacy and continued leadership in haemophilia care. Sobi addresses the high unmet medical needs of patients by advancing a pipeline of innovative medicines and working to expand patient access globally. The company's mission is to transform the lives of people affected by rare conditions through dedicated research, development, and global collaboration.

Recent filings

Filing Released Lang Actions
Interim / Quarterly Report 2024
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Delårsrapport för tredje kvartalet 2024' (Interim Report for the third quarter of 2024). It contains comprehensive financial statements, including income statements, revenue breakdowns by segment, and management commentary on performance for the quarter and the nine-month period. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). Q3 2024
2024-10-24 Swedish
Earnings Release 2024
Earnings Release Classification · 100% confidence The document explicitly states it is the "Q3 2024 report" and contains detailed financial tables comparing Q3 2024 results with Q3 2023, including revenue, EBITA, EPS, and updated outlook for 2024. It provides comprehensive financial performance analysis for a period shorter than a full year (the third quarter). This structure aligns perfectly with the definition of an Interim / Quarterly Report (IR). It is not a brief announcement (RPA/RNS) as it contains the full substance of the results, nor is it the Annual Report (10-K). Q3 2024
2024-10-24 English
New number of shares and votes in Sobi
Share Issue/Capital Change Classification · 100% confidence The document is a press release announcing a change in the total number of shares and votes in Sobi as of 30 September 2024. It explicitly mentions the issuance of class C shares and their conversion to common shares to fulfill incentive program commitments. This falls under the category of share capital changes and share issues.
2024-09-30 English
Ändring av antalet aktier och röster Sobi
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Swedish Orphan Biovitrum AB (Sobi) announcing a change in the total number of shares and votes due to the issuance and conversion of C-shares. This type of disclosure regarding changes in share capital and voting rights is a standard regulatory requirement for listed companies, falling under the category of share issues or capital changes.
2024-09-30 Swedish
Sobi har genomfört emissioner av C-aktier
Capital/Financing Update Classification · 98% confidence The document text, written in Swedish, announces that Sobi has completed the issuance and subsequent repurchase/conversion of C-shares ('C-aktier') related to incentive programs, following a decision made at the Annual General Meeting (AGM) on May 14, 2024. The core subject is the issuance and subsequent capital structure change involving these specific shares, including the total number of shares involved (1,641,103) and the resulting number of treasury shares held by Sobi. This directly relates to changes in the company's capital structure and financing activities, specifically the execution of a plan approved at the AGM concerning share issuance and repurchase. This aligns best with the 'Capital/Financing Update' category (CAP), as it details the completion of a share issuance and subsequent buyback mechanism designed to fulfill obligations under incentive programs.
2024-08-29 Swedish
Sobi has completed issues of class C shares
Transaction in Own Shares Classification · 95% confidence The document explicitly details a corporate action involving the issuance and subsequent repurchase of Class C shares, which were authorized by the Annual General Meeting (AGM) to secure obligations under incentive programs. The core subject is the completion of a share transaction (subscription and payment for repurchase of 1,641,103 Class C shares). This directly relates to changes in the company's capital structure and the management of its own shares. While it mentions the AGM resolution, the primary focus is the execution of the share repurchase/issue. This aligns best with the 'Share Issue/Capital Change' (SHA) or 'Transaction in Own Shares' (POS) definitions. Since the text focuses on the completion of the repurchase of issued shares (a transaction in own shares), POS is the most precise fit. It is not a general financing update (CAP) but a specific transaction involving treasury stock management.
2024-08-29 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.